{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-243039","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2025-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.848349+00:00","generated_at":"2026-05-17T03:13:39.703709+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Viridian Therapeutics secures up to $600M via royalty sale and debt facility","bullets":["DRI Healthcare pays $55M upfront for U.S. revenue rights; up to $300M total tied to VRDN-003 milestones and FDA approval.","Tiered royalties on veligrotug/VRDN-003 net sales: 7.5% up to $600M, then declining to zero above $2B.","Hercules Capital provides $300M term loan facility; $50M drawn at close, with tranches up to $300M depending on milestones.","Loan bears interest at prime+1.45% (floor 8.95%, cap 9.45%), maturity 2030, interest-only through 2029/2030.","Combined financing strengthens balance sheet for pivotal clinical trials and pre-commercial activities."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-243039","json":"https://secwatch.observer/filing/0001193125-25-243039.json","markdown":"https://secwatch.observer/filing/0001193125-25-243039.md","text":"https://secwatch.observer/filing/0001193125-25-243039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525243039/0001193125-25-243039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525243039/d20179d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:13:39.703709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}